Ocugen Secures Full $130M Convertible Note Offering, Extends Cash Runway to 2028
OCGN has more than doubled off its 52-week low of $0.64.
Summary
Ocugen finalized its $130 million convertible note offering, including a $15 million over-allotment, securing $112.6 million in net proceeds to repay debt and extend its cash runway into 2028.
Key Events · Financing and Capital Events · OCGN
-
Full Offering Completed
Ocugen closed its private offering of 6.75% Convertible Senior Notes due 2034, totaling $130.0 million in aggregate principal amount.
-
Over-Allotment Option Exercised
The initial purchaser fully exercised its option to purchase an additional $15.0 million in notes, completing the offering that was initially announced with this option.
-
Significant Net Proceeds
The offering is expected to result in approximately $112.6 million in net proceeds for Ocugen.
-
Debt Repayment & Cash Runway Extended
Approximately $32.7 million of the net proceeds were used to fully repay an outstanding loan, and the remaining funds are expected to extend the company's cash runway into 2028.
Analysis · OCGN · Life Sciences
This filing confirms the full exercise of the over-allotment option for Ocugen's convertible senior notes, bringing the total offering to $130 million. The net proceeds of $112.6 million significantly bolster the company's liquidity, allowing it to repay $32.7 million in debt and extend its cash runway into 2028. This is a critical development for a company that recently disclosed a "going concern" warning, providing essential funding to advance its late-stage gene therapy pipeline.
At the time of this filing, OCGN was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $494.2M. The 52-week trading range was $0.64 to $2.73. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.